• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非清髓性预处理造血干细胞移植后髓外白血病复发

Extramedullary leukemic relapses following hematopoietic stem cell transplantation with nonmyeloablative conditioning.

作者信息

Ruiz-Argüelles Guillermo J, Gómez-Almaguer David, Vela-Ojeda Jorge, Morales-Toquero Amelia, Gómez-Rangel Jóse David, García-Ruiz-Esparza Miriam A, López-Martínez Briceida, Cantú-Rodríguez Olga G, Gutiérrez-Aguirrec César H

机构信息

Centro de Hematología y Medicina Interna de Puebla, Puebla, PUE, Mexico.

出版信息

Int J Hematol. 2005 Oct;82(3):262-5. doi: 10.1532/IJH97.04195.

DOI:10.1532/IJH97.04195
PMID:16207602
Abstract

Of a group of 149 patients who underwent allogeneic stem cell transplantation using the "Mexican approach", a nonablative preparative regimen, 49 individuals developed bone marrow relapse, and 8 patients developed extramedullary relapse (EMR). All EMR cases presented in patients who received allografts for myeloid malignancies. In contrast, bone marrow relapses presented in patients with myeloid or lymphoid malignancies. EMR presented 60 to 1010 days after the allograft and appeared in 3 cases as subcutaneous nodules in different parts of the body, in the vertebrae in 3 cases, and in the kidney and the breast in 1 case each. One patient had both subcutaneous nodules and epididymis EMR. When EMR was noted, acute graft-versus-host disease (GVHD) had presented in 4 patients, and limited forms of chronic GVHD were present in 3 patients. All but 1 of the patients were full chimeras when the EMR ensued, and the EMR preceded an overt hematologic relapse in all but 1 of the patients. Patients who experienced an overt hematologic relapse died 20 to 180 days (median, 40 days) after the EMR. The only individual alive 240 days after relapse shows no evidence of a full-blown hematologic relapse. An EMR after allogeneic hematopoietic stem cell transplantation usually has a bad prognosis and presents mainly in individuals with high-risk malignancies.

摘要

在一组149例采用“墨西哥方法”(一种非清髓性预处理方案)进行异基因干细胞移植的患者中,49例发生骨髓复发,8例发生髓外复发(EMR)。所有EMR病例均出现在接受髓系恶性肿瘤同种异体移植的患者中。相比之下,骨髓复发则出现在髓系或淋巴系恶性肿瘤患者中。EMR发生在移植后60至1010天,3例表现为身体不同部位的皮下结节,3例出现在椎骨,1例出现在肾脏和乳腺。1例患者既有皮下结节又有附睾EMR。发现EMR时,4例患者出现了急性移植物抗宿主病(GVHD),3例患者存在局限性慢性GVHD。除1例患者外,所有患者在发生EMR时均为完全嵌合体,除1例患者外,所有患者的EMR均先于明显的血液学复发。发生明显血液学复发的患者在EMR后20至180天(中位值40天)死亡。复发后240天仍存活的唯一患者没有出现明显血液学复发的迹象。异基因造血干细胞移植后的EMR通常预后不良,主要发生在高危恶性肿瘤患者中。

相似文献

1
Extramedullary leukemic relapses following hematopoietic stem cell transplantation with nonmyeloablative conditioning.非清髓性预处理造血干细胞移植后髓外白血病复发
Int J Hematol. 2005 Oct;82(3):262-5. doi: 10.1532/IJH97.04195.
2
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
3
Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia.异基因造血干细胞移植后急性白血病的髓外复发:急性髓系白血病与急性淋巴细胞白血病的不同特征
Biol Blood Marrow Transplant. 2014 Jul;20(7):1040-7. doi: 10.1016/j.bbmt.2014.03.030. Epub 2014 Apr 2.
4
Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes.单倍体相合造血干细胞移植后急性白血病的髓外复发:发生率、危险因素、治疗及临床结局
Biol Blood Marrow Transplant. 2014 Dec;20(12):2023-8. doi: 10.1016/j.bbmt.2014.08.023. Epub 2014 Sep 6.
5
[Risk factors of extramedullary relapse after allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemia].[髓系白血病患者异基因造血干细胞移植后髓外复发的危险因素]
Zhonghua Nei Ke Za Zhi. 2021 Jan 1;60(1):41-44. doi: 10.3760/cma.j.cn112138-20200303-00174.
6
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.高危急性白血病异基因造血干细胞移植中标准与替代清髓性预处理方案的比较
Haematologica. 2002 Jan;87(1):52-8.
7
Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.在成人急性髓系白血病患者中,异基因干细胞移植后发生髓外复发的比例高于化疗后。
Leuk Res. 2013 Nov;37(11):1477-81. doi: 10.1016/j.leukres.2013.08.017. Epub 2013 Sep 5.
8
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.异基因造血干细胞移植后巨细胞病毒再激活与移植后存活至第100天的急性髓系白血病患者复发风险降低相关:日本造血细胞移植学会移植相关并发症工作组
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
9
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.一项关于采用降低强度预处理方案,随后进行异基因干细胞移植治疗血液系统恶性肿瘤患者的研究,该方案使用Campath-1H作为移植物抗宿主病策略的一部分。
Biol Blood Marrow Transplant. 2006 Aug;12(8):868-75. doi: 10.1016/j.bbmt.2006.05.006.
10
Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?异基因干细胞移植后复发的慢性髓性白血病供体淋巴细胞输注:我们能否在不发生移植物抗宿主病的情况下预测移植物抗白血病作用?
Biol Blood Marrow Transplant. 2015 Jul;21(7):1230-6. doi: 10.1016/j.bbmt.2015.03.012. Epub 2015 Mar 19.

引用本文的文献

1
Radiological imaging characteristics of intramammary hematological malignancies: results from a german multicenter study.乳腺血液恶性肿瘤的放射影像学特征:德国多中心研究结果。
Sci Rep. 2017 Aug 7;7(1):7435. doi: 10.1038/s41598-017-07409-z.
2
Multiple isolated extramedullary relapse of acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplant: a case report and review of literature.异基因造血干细胞移植后急性早幼粒细胞白血病的多次孤立性髓外复发:一例报告并文献复习
Springerplus. 2013 Dec;2(1):49. doi: 10.1186/2193-1801-2-49. Epub 2013 Feb 12.
3
Extramedullary relapse following reduced intensity allogeneic hematopoietic cell transplant for adult acute myelogenous leukemia.

本文引用的文献

1
Breaking dogmata to help patients: non-myeloablative haematopoietic stem cell transplantation.打破教条以帮助患者:非清髓性造血干细胞移植
Expert Opin Biol Ther. 2004 Oct;4(10):1693-9. doi: 10.1517/14712598.4.10.1693.
2
Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.异基因骨髓移植后复发的急性髓系白血病采用化疗后予粒细胞集落刺激因子动员的供者白细胞输注治疗:孤立性髓外复发发生率高。
Leukemia. 2004 Nov;18(11):1789-97. doi: 10.1038/sj.leu.2403523.
3
Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: a prospective study.
成人急性髓性白血病接受减低强度异基因造血细胞移植后的髓外复发
Leuk Lymphoma. 2013 Mar;54(3):665-8. doi: 10.3109/10428194.2012.720375. Epub 2012 Sep 12.
适用于传统同种异体移植的急性髓性白血病患者接受非清髓性预处理的异基因造血干细胞移植:一项前瞻性研究。
Leuk Lymphoma. 2004 Jun;45(6):1191-5. doi: 10.1080/10428190310001642846.
4
Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course.异基因造血细胞移植后急性白血病的骨髓复发与髓外复发:危险因素及临床病程
Bone Marrow Transplant. 2003 Oct;32(8):835-42. doi: 10.1038/sj.bmt.1704223.
5
Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study.急性淋巴细胞白血病中采用减低剂量预处理的异基因造血干细胞移植:一项可行性研究。
Haematologica. 2003 May;88(5):555-60.
6
Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.异基因干细胞移植、大剂量阿糖胞苷及自体外周血干细胞移植作为初治急性髓系白血病患者缓解后治疗的比较
Cancer. 2003 Apr 1;97(7):1721-31. doi: 10.1002/cncr.11240.
7
Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review.非清髓性异基因干细胞移植治疗血液系统恶性肿瘤:一项系统评价
Cancer Control. 2003 Jan-Feb;10(1):17-41. doi: 10.1177/107327480301000104.
8
Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.“微移植”综述:非清髓性异基因造血干细胞移植
Int J Hematol. 2003 Jan;77(1):3-14. doi: 10.1007/BF02982597.
9
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.非清髓性异基因干细胞移植治疗慢性髓性白血病慢性期。
Blood. 2003 Jan 15;101(2):441-5. doi: 10.1182/blood-2002-02-0535. Epub 2002 Sep 19.
10
Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: a prospective study in a single institution.采用免疫抑制、非清髓性预处理方案的异基因造血干细胞移植受者造血嵌合状态的随访:单中心前瞻性研究
Leuk Lymphoma. 2002 Jul;43(7):1509-11. doi: 10.1080/10428190290033549.